In-depth Full-process Analysis of Professional Agency Services for Export of Beijing Biopharmaceutical Intermediates to the EU

Current Market Status and Core Barriers for Beijing Pharmaceutical Intermediates Export to EU

In the first quarter of 2026,the value of pharmaceutical intermediates exported from Beijing port to the EU increased by 18.7% year-on-year,while the return rate also climbed to 4.3% in the same period.Behind this contrast is the newly revised Annex XVII of REACH Regulation by the European Chemicals Agency (ECHA),which raised the impurity limit standard for pharmaceutical intermediates by 30%.Manager Yan from a Beijing biopharmaceutical enterprise revealed that a batch of API intermediates worth 2 million euros from his company was detained for 17 days at Rotterdam Port because the flash point data in the SDS did not comply with the latest EU CLP Regulation classification standard,and eventually incurred more than 150,000 euros in port storage fees and testing fees.

The common challenges currently faced by Beijing enterprises are concentrated in three aspects: First,outdated awareness of regulations.The 12 newly added entries on the EU SVHC list in 2026 directly affect more than 60% of pharmaceutical intermediate formulations.Second,disjointed document connection.The mutual recognition rules for Beijing’s certificate of origin,health certificate and EU CEP certificate are complex,and an average of 23 supporting documents are required per batch.Third,slow customs clearance response.EU customs maintains a high 22% inspection rate for pharmaceutical goods,and under the traditional customs declaration mode,it takes an average of 9.3 working days from inspection to release.These problems directly push the compliance cost of small and medium-sized Beijing enterprises exporting to the EU to 8%-12% of the total cargo value,far higher than other regional markets.

Three-dimensional Value System of Zhongshen’s Export Agency Service

In response to the above pain points,Zhongshen upgraded its special service for pharmaceutical intermediates export to EU in 2026.The biopharmaceutical team led by Manager Yan converted 20 years of customs declaration and inspection experience into quantifiable service indicators: document pre-review accuracy reaches 99.2%,EU port customs clearance time is controlled within 5 working days,and the export tax refund arrival cycle is shortened to 35 days.This capability is built on the in-depth construction of three dimensions.

The first dimension is the dynamic regulation tracking system.Zhongshen has set up a regulatory information monitoring point in Brussels,which updates weekly on EDQM certificate changes,CEP review progress and special requirements of member state customs.In March 2026,this system issued an early warning 40 days in advance of the import license adjustment for a certain anti-tumor drug intermediate by the German Federal Institute for Drugs and Medical Devices (BfArM),helping three Beijing clients adjust their formulas in time and avoiding order losses of about 8 million euros.

The second dimension is the intelligent document matching engine.Under the traditional mode,a complete EU export document package requires 6-8 hours of manual verification.The pharmaceutical intermediate document matrix developed by Zhongshen logically links 47 key fields including REACH registration number,CEP certificate number,TARIC code,etc.and compresses automatic verification time to 23 minutes.After adopting this system,a Beijing vaccine excipient enterprise served by Manager Yan’s team had zero customs detention incidents caused by inconsistent documents among 18 batches exported to the EU in Q2 2026.

The third dimension is the port resource collaboration network.Zhongshen has established direct connection channels with 12 AEO advanced certified customs brokers at the three major ports of Rotterdam,Hamburg and Antwerp,realizing pre-declaration before departure from Beijing,priority inspection after arrival,and automatic push of electronic bill of lading after release.This layout reduces the average stay time of pharmaceutical intermediates at EU ports from 11.5 days to 4.2 days.

Service Module Breakdown: Responding to Special EU Requirements in Document Preparation

REACH Regulation Compliance Pre-review Mechanism

EU’s REACH registration requirements for pharmaceutical intermediates show two major changes in 2026: First,complete Chemical Safety Report (CSR) is required for substances with annual export volume of 1-10 tons.Second,products containing nanocomponents are mandatory to submit the filing receipt of the European Union Observatory for Nanomaterials (EUON).Zhongshen’s document pre-review service first verifies the validity of the REACH registration number provided by the client,and verifies the coverage of registered tonnage in real time through ECHA’s REACH-IT system.

Manager Yan handled a typical case: the fluorinated benzoic acid intermediate exported by a Beijing enterprise had a REACH registered tonnage of 1-10 tons/year,but the actual order volume in 2026 reached 9.8 tons,approaching the registration upper limit.Zhongshen detected the risk in the pre-review stage and guided the client to complete tonnage update before export,avoiding a fine of 50,000 euros for over-tonnage export.The pre-review mechanism also includes special review of the transportation information in Part 14 of SDS,ensuring that the UN number and packing group meet the latest ADR requirements.

Connection Rules between CEP Certificate and Certificate of Origin

EU adopts a dual-track system of CEP certificate and GMP certificate for quality certification of pharmaceutical intermediates.In 2026,EDQM increased the frequency of on-site inspections for CEP certificates by 40%,and the inspection focus has shifted to supply chain traceability of starting materials.Zhongshen’s service includes cross-comparison of 12 key process parameters listed in Annex A of the CEP certificate,ensuring that the batch records submitted by Beijing manufacturers are consistent with the certificate statement.

In terms of certificate of origin,Zhongshen uses the cumulation rule in the China-EU preferential trade agreement to help Beijing enterprises reasonably declare origin standards.For example,a Beijing enterprise purchases primary intermediates from Hebei and conducts refining processing in Beijing.By calculating the Regional Value Content (RVC) ratio,Zhongshen successfully helped the enterprise apply for a Form A certificate of origin,reducing the client’s import tariff in the EU from 6.5% to 3.2%,saving about 43,000 euros in tariff for a single batch.

Service Module Breakdown: Breaking EU Barriers in Customs Clearance Process

Pre-emptive Response to EDQM Sampling Inspection

In 2026,the EU increased the port sampling ratio of pharmaceutical intermediates from 15% to 22%,and the testing cycle after sending samples to EDQM laboratory is as long as 25-30 working days.Zhongshen’s response strategy is a "pre-placement compliance document package",which prepares three sets of documents in parallel before cargo shipment: COA analysis report from a Beijing laboratory,re-inspection report from an EU-recognized third-party laboratory,and GMP compliance statement for the entire production process of the batch.

A Beijing antibiotic intermediate exporter served by Manager Yan’s team was sampled by Dutch customs in April 2026.Thanks to the complete compliance document package prepared in advance by Zhongshen,after reviewing the documents,customs officials shortened the sample testing cycle from the standard 25 working days to 7 working days,reducing the cargo stay time by 12 days.Under this model,the release rate after sampling inspection for Zhongshen’s clients increased from the industry average of 67% to 94%.

Resource Deployment of Port Priority Channel

The core advantage of Zhongshen’s customs clearance cooperation network at three major EU ports lies in the inspection convenience brought by AEO mutual recognition.In 2026,Zhongshen assisted a Beijing vitamin D3 intermediate enterprise to apply for AEO-C certification from Dutch customs,reducing the enterprise’s inspection rate at Rotterdam Port from 28% to 9%.For non-AEO clients,Zhongshen uses the priority channel of cooperative customs brokers to ensure that document review is completed within 24 hours after arrival,and physical inspection (if triggered) is completed within 48 hours for pharmaceutical intermediate cargo.

This resource deployment capability is particularly valuable in emergency scenarios.In May 2026,a batch of intermediates for rare disease drugs from a Beijing enterprise arrived at the port behind schedule due to flight delay,missing the client’s production line scheduling.Manager Yan activated Zhongshen’s emergency customs clearance plan,coordinated the port to arrange overtime inspection,completed all procedures on Sunday,ensuring that the goods were delivered to the German client’s factory early on Monday,avoiding production line shutdown losses.

Service Module Breakdown: Speed Revolution of Export Tax Refund

Accurate Classification Code Matching and Maximum Tax Refund Rate

In 2026,the State Taxation Administration of China adjusted the export tax refund rate of pharmaceutical intermediates slightly.The tax refund rate for some high value-added products increased from 13% to 15%,but requires enterprises to provide high-tech product certification issued by the Ministry of Science and Technology.Zhongshen’s tax refund service first accurately classifies the client’s pharmaceutical intermediates through an intelligent tariff system,avoiding tax refund losses caused by incorrect HS code application.

In a case operated by Manager Yan,a Beijing enterprise’s heterocyclic intermediate was originally declared under 2933.3990 with a 13% tax refund rate.By analyzing the product’s molecular structure and use certification,Zhongshen reclassified it to 2933.5990 with a 15% tax refund rate,increasing the tax refund by about 87,000 RMB for a single batch.The system can also automatically match Beijing’s local government export incentive policies and calculate the actual combined income.

Paperless Declaration and Direct Treasury Connection Channel

The export tax refund 3.0 system launched by Zhongshen in 2026 has realized direct three-party connection with Beijing Municipal Taxation Bureau’s electronic account library and national treasury payment system.Under the traditional mode,after an enterprise submits a tax refund application,it needs to go through five links: tax acceptance,review,re-review,approval and refund,which takes an average of 55 working days.Through the pre-review mechanism,Zhongshen completes all document matching within 24 hours after the export customs declaration is issued,and compresses the review cycle to 10 working days by using the tax bureau’s green channel.

Data provided by Manager Yan shows that in the first half of 2026,the average tax refund arrival time for Beijing pharmaceutical intermediate export business agency handled by Zhongshen is 35 working days,43% faster than the Beijing average of 62 working days.For small and medium-sized enterprises in urgent need of capital turnover,Zhongshen also provides tax refund factoring financing service,which advances 80% of the tax refund within 3 working days after the tax refund application is submitted,solving cash flow pressure.

Empirical Data of Efficiency Improvement and Cost Optimization Model

In the comprehensive benefit evaluation of Q2 2026,Beijing pharmaceutical intermediate export enterprises served by Zhongshen showed significant improvements in three dimensions.In terms of customs clearance efficiency,the average customs clearance cycle decreased from the industry benchmark of 11.5 days to 5.2 days,and the fastest for AEO-certified clients is 3.8 days.In terms of capital turnover,the tax refund arrival cycle shortened from 60 days to 35 days,directly reducing financial costs by about 1.2 percentage points.In terms of compliance risk,the customs detention rate caused by inconsistent documents decreased from 8.7% to 0.9%,avoiding an average additional cost of 93,000 RMB per order.

Customized Service Path and Decision Recommendations

The market of Beijing pharmaceutical intermediates exported to the EU shows an obvious differentiation trend in 2026.Large enterprises with annual export volume above 5 million euros tend to build their own compliance system,but need agency services to solve unexpected customs clearance problems; medium-sized enterprises with annual export volume of 500,000 to 5 million euros need full-process trustee service most to reduce labor costs; micro enterprises with annual export volume below 500,000 euros have urgent demand for tax refund financing and document agency.

Zhongshen has designed differentiated service packages for these three types of clients.For large enterprises,we provide lightweight "emergency customs clearance + regulation early warning" services,charged per order,with a single customs clearance agency fee of about 12,000-18,000 RMB; for medium-sized enterprises,we provide standard "documents + customs clearance + tax refund" services with annual fee model,and the annual service fee is about 180,000-250,000 RMB; for micro enterprises,we provide basic "document agency + tax refund financing" services,charged per order,with a service fee of about 3,000-5,000 RMB per order.

Manager Yan recommends that when selecting export agency services,Beijing enterprises should focus on three matching points: first,the update frequency of the agency’s mastery of EU pharmaceutical regulations,second,the depth of its customs clearance resources in EU ports,third,the capital advance capability of tax refund services.Zhongshen provides verifiable case data and written commitments in all three dimensions.

In the second half of 2026,the EU plans to put forward new requirements for carbon footprint disclosure of pharmaceutical intermediates,which will bring new compliance costs to Beijing export enterprises.Zhongshen has already started the connection of carbon footprint accounting system,and will provide carbon label certification agency service simultaneously when the EU regulation takes effect.For Beijing enterprises that want to stabilize their EU market share,choosing an agency partner with forward-looking service capability now is a key decision to cope with future barriers.